A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

Cancer incidence and mortality in China, 2006

(2011) Wan-qing Chen et al.   Chinese Journal of Cancer Research

High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area

(2011) Tai-Jan Chiu et al.   Journal of Translational Medicine

Thymidine synthase, thymidine phosphorylase and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

(2010) S Lee et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie

(2009) S. Lorenzen et al.   ANNALS OF ONCOLOGY

ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer

(2007) Tetsuya Fujii et al.   LUNG CANCER